Press Releases

BETHESDA, Md., May 31, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will... Read More

Median survival of top 100 patients is 40.5 months, Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Md., May 29, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L... Read More

Large Voter Turn-Out and Landslide Approval Of All Proposals   BETHESDA, Md., May 1, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC. Voter turnout was 74% of all... Read More

 CEO Increases Year to Date Funding to $5.4 Million   BETHESDA, Md., April 30, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, increased her funding to the Company by $1 million, reaching a total of $5.4 million this year to date. On April 26, 2018, the Company and Ms. Powers entered into a... Read More

Financing Responds to Shareholder Requests Following Recent Series A Preferred Stock Financing BETHESDA, Md., December 19, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) — (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution... Read More